Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmacyclics has entered into a five-year cooperative research and development agreement (CRADA) with the National Cancer Institute (NCI) to develop PCI-32765 as a treatment for hematologic malignancies (blood cancers).
Subscribe to our email newsletter
As per the terms of the CRADA, Division of Cancer Treatment and Diagnosis (DCTD) of NCI intends to sponsor PCI-32765 Phase 1 and Phase 2 trials in certain hematologic malignancies, including multiple myeloma and non-Hodgkin lymphoma (NHL).
Pharmacyclics Oncology Development vice president Eric Hedrick said this CRADA represents a major achievement for the company, and allows them to broaden their knowledge of PCI-32765 based on clinical trials to be performed by leading investigators in the field of hematologic malignancies.